Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9886817 | 1.00 | MEN1 (0.47) | MEN1KMT2ATDP1SMYD2ALDH1A1 | |
| SCHEMBL20500291 | 1.00 | MEN1 (0.47) | MEN1KMT2ATDP1SMYD2ALDH1A1 | |
| SCHEMBL28346561 | 0.88 | SMYD2 (0.40) | MEN1KMT2ATDP1SMYD2CYP3A4 | |
| SCHEMBL19397922 | 0.86 | SMYD2 (0.40) | MEN1KMT2ATDP1SMYD2ALDH1A1 | |
| SCHEMBL8166048 | 0.85 | SMYD2 (0.38) | MEN1KMT2ATDP1SMYD2ALDH1A1 | |
| SCHEMBL24454456 | 0.85 | SMYD2 (0.40) | MEN1KMT2ASMYD2CYP3A4SMN1; SMN2 | |
| SCHEMBL21491785 | 0.84 | SMYD2 (0.39) | MEN1KMT2ATDP1SMYD2ALDH1A1 | |
| SCHEMBL21491783 | 0.84 | SMYD2 (0.39) | MEN1KMT2ATDP1SMYD2ALDH1A1 | |
| SCHEMBL21491787 | 0.84 | SMYD2 (0.39) | MEN1KMT2ATDP1SMYD2ALDH1A1 | |
| SCHEMBL1564475 | 0.84 | SMYD2 (0.39) | MEN1KMT2ATDP1SMYD2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415770-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | Emory University, Office of Technology Transfer (US) | 2025-09-16 | — | — | US | disclosed |
| WO-2025132542-A1 | MACROCYCLIC OREXIN AGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-06-26 | — | — | WO | disclosed |
| EP-4516774-A2 | MODULATORS OF LIVER RECEPTOR HOMOLOGUE 1 (LRH-1) AND USES | Emory University (US) | 2025-03-05 | — | — | EP | disclosed |
| EP-3595652-B1 | MODULATORS OF LIVER RECEPTOR HOMOLOGUE 1 (LRH-1) | UNIV EMORY (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240368066-A1 | MODULATORS OF LIVER RECEPTOR HOMOLOGUE 1 (LRH-1) AND USES | EMORY UNIVERSITY | 2024-11-07 | — | — | US | disclosed |
| US-12065402-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | EMORY UNIVERSITY (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240158412-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | FAXIAN THERAPEUTICS, LLC | 2024-05-16 | — | — | US | disclosed |
| EP-4288442-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | Faxian Therapeutics, LLC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230295070-A1 | Modulators of Liver Receptor Homologue 1 (LRH-1) and Uses | EMORY UNIVERSITY | 2023-09-21 | — | — | US | disclosed |
| US-11691939-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | EMORY UNIVERSITY (US) | 2023-07-04 | — | — | US | disclosed |
| US-10843996-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | EMORY UNIVERSITY (US) | 2020-11-24 | — | — | US | disclosed |
| WO-2018170430-A1 | MODULATORS OF LIVER RECEPTOR HOMOLOGUE 1 (LRH-1) AND USES | EMORY UNIVERSITY (US) | 2018-09-20 | — | — | WO | disclosed |
| EP-2647617-B1 | NUCLEOSIDE ANALOG OR SALT THEREOF, OLIGONUCLEOTIDE ANALOG, GENE EXPRESSION INHIBITOR, AND NUCLEIC-ACID PROBE FOR DETECTING GENE | JAPAN SCIENCE & TECH AGENCY (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-8865898-B2 | Nucleoside analog or salt thereof, oligonucleotide analog, gene expression inhibitor, and nucleic-acid probe for detecting gene | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-21 | — | — | US | disclosed |
| US-20140221637-A1 | NUCLEOSIDE ANALOG OR SALT THEREOF, OLIGONUCLEOTIDE ANALOG, GENE EXPRESSION INHIBITOR, AND NUCLEIC-ACID PROBE FOR DETECTING GENE | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-08-07 | — | — | US | disclosed |
| EP-2647617-A1 | NUCLEOSIDE ANALOG OR SALT THEREOF, OLIGONUCLEOTIDE ANALOG, GENE EXPRESSION INHIBITOR, AND NUCLEIC-ACID PROBE FOR DETECTING GENE | Japan Science And Technology Agency (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-6602861-B1 | Acylated phospholipid drugs | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2003-08-05 | — | — | US | disclosed |
| US-5846955-A | Acylated phospholipid drugs | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-12-08 | — | — | US | disclosed |
| EP-0636134-B1 | NOVEL ACYLATED PHOSPHOLIPID DRUGS | RES CORP TECHNOLOGIES INC (US) | 1997-12-17 | — | — | EP | disclosed |
| EP-0514036-A2 | Preparation of thionucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158412-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | USP7, USP28, USP1 | MEN1 2757/4885KMT2A 869/4885TDP1 914/4885 |
| US-20240368066-A1 | MODULATORS OF LIVER RECEPTOR HOMOLOGUE 1 (LRH-1) AND USES | NR1H2, NR1H3, NR1H4 | MEN1 3434/4885KMT2A 2109/4885TDP1 3492/4885 |
| US-12415770-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | NR1H2, NR1H3, NR1H4 | MEN1 3434/4885KMT2A 2109/4885TDP1 3492/4885 |
| US-20230295070-A1 | Modulators of Liver Receptor Homologue 1 (LRH-1) and Uses | NR1H2, NR1H3, NR1H4 | MEN1 3434/4885KMT2A 2109/4885TDP1 3492/4885 |
| US-11691939-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | NR1H2, NR1H3, NR1H4 | MEN1 3434/4885KMT2A 2109/4885TDP1 3492/4885 |
| US-12065402-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | NR1H2, NR1H3, NR1H4 | MEN1 3434/4885KMT2A 2109/4885TDP1 3492/4885 |
| US-10843996-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | NR1H2, NR1H3, NR1H4 | MEN1 3434/4885KMT2A 2109/4885TDP1 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.